<DOC>
	<DOCNO>NCT00061711</DOCNO>
	<brief_summary>This randomize , control trial evaluate efficacy safety three alternative approach utilize phytoestrogens treat hot flash night sweat peri- post-menopausal woman . The treatment choose scientific evidence support possible benefit , availability product adequate quality control , frequency use naturopathic medicine . RECRUITMENT FOR THIS STUDY SHOULD END BY AUGUST 1 , 2003 .</brief_summary>
	<brief_title>Alternative Therapies Menopause : A Randomized Trial</brief_title>
	<detailed_description>Over 17 million U.S. woman peri- post-menopausal age range ( 45 - 55 ) , year 2015 nearly half U.S. woman post-menopausal . Of , 25-33 % experience moderate severe menopausal symptom , face decision related maintain health mid-life beyond . Hormone Replacement Therapy ( HRT ) standard pharmacologic intervention menopausal symptom therapy measure . Concerns breast cancer thromboembolism risk , need safe alternative symptom relief among woman HRT contraindicate , resistance HRT due side effect fuel search alternative . The primary aim randomize , control trial compare effect three alternative treatment utilize phytoestrogens , HRT , placebo frequency intensity vasomotor symptom measure Wiklund Menopause Symptom Checklist daily vasomotor symptom diary . The alternative treatment choose study single herbal formula black cohosh , multibotanical formula contain black cohosh , alfalfa , boron , chasteberry , dong quai , false unicorn , licorice , oat , pomegranate , Siberian ginseng , soy diet counsel addition multibotanical formula . The finding Women 's Health Initiative study publish July 2002 give medical research communities new information long-term risk HRT use . In response finding , study design allow woman randomize either 5-arm trial include HRT , randomize 4 5 arm : one three herbal group placebo , without chance assign HRT . Secondary aim compare effect three alternative treatment , HRT , placebo : 1. vaginal cytology ( vaginal maturation index ) 2. serum lipid ( total cholesterol , HDL LDL cholesterol , triglyceride ) 3. bone mineral density ( hip spine dual energy x-ray absorptiometry scan ) 4. glucose metabolism ( insulin , fast blood glucose ) 5. clot factor ( fibrinogen , PAI-1 ) . Approximately 400 peri- post-menopausal woman recruit randomized one 5 one 4 treatment arm one year . Primary secondary outcome measure baseline , 3 , 6 , 12 month . Changes outcomes compare group take alternative treatment HRT placebo group .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Phytoestrogens</mesh_term>
	<criteria>Inclusion Criteria 1 . Female , age 4555 . 2 . Peri postmenopausal , define menstrual period least 12 month prior study entry , skip least one menstrual period 12 month prior study entry . Peri postmenopausal status determine candidate uterus remove assessment blood follicle stimulate hormone ( FSH ) . Women FSH level high 20 mlU/mL eligible study . 3 . Experiencing average 2 hot flash night sweat per day , 6 must moderate great intensity two week . 4 . Normal thyroid stimulate hormone ( TSH ) measure prior study entry , define 0.4 5.0 ulU/ML . 5 . Proof negative mammogram within two year prior randomization . Subjects may provide copy mammogram result letter primary care provider . 6 . Must provide informed consent . 7 . Not high risk medical complication might affect subject 's ability complete trial without serious comorbid event , base medical history , physical examination laboratory screen evaluation . Exclusion Criteria 1 . Mentally legally incapacitate informed consent obtain . 2 . Use hormone replacement therapy oral contraceptive within past three month . 3 . Use alternative complementary medicine herbs menopausal symptom within past one month . 4 . History illness significant abnormality prestudy clinical laboratory evaluation opinion investigator participate study might pose unacceptable risk subject . 5 . The subject medical history follow contraindication HRT : breast cancer , uterine cancer , endometrial hyperplasia , angina treated medication , myocardial infarction , revascularization surgery , coronary angioplasty , stroke , blood clot , active chronic liver disease , nephrotic syndrome . 6 . Bone mineral density hip spine two standard deviation agespecific mean . 7. bilateral oophorectomy . 8 . Current use follow medication : tamoxifen , raloxifene , bisphosphonates , cholesterollowering medication , prescription bloodthinners , oral steroid . 9 . Pregnant plan become pregnant . 10 . Baseline blood pressure great 160/95 mm Hg . 11 . Alergy soybean soy protein . 12 . Unable swallow pill . 13 . Current participation another investigational drug trial . 14 . Intention move within next 12 month render followup per protocol impossible . 15 . Noncompliance procedure involve screen visit runin trial . To compliant , subject must take least 80 % runin medication ( miss 21/2 day ) complete least 80 % baseline symptom diary ( miss 3 day hot flash night sweat diary , must complete Wiklund checklist ) .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>